🟢 EIQ.AX is trading 33% up today on expectations of imminent FDA clearance for EchoSolv-HF

EIQ.AX is trading 33% up at A$1.65 following a sharp speculative rally linked to expectations of an imminent U.S. FDA 510(k) decision on its EchoSolv-HF heart failure AI diagnostic tool.

• Investors are reacting to commentary and prior guidance suggesting FDA clearance for EchoSolv-HF could arrive in early 2026.
• The diagnostic tool builds on Echo IQ’s existing FDA-cleared aortic stenosis AI platform and follows recent strong validation results.